Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
Status:
Active, not recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This randomized phase III trial studies how well blinatumomab works compared with standard
combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that
has returned after a period of improvement (relapsed). Immunotherapy with blinatumomab, may
induce changes in body's immune system and may interfere with the ability of tumor cells to
grow and spread. It is not yet known whether standard combination chemotherapy is more
effective than blinatumomab in treating relapsed B-cell acute lymphoblastic leukemia.